|
gptkbp:instanceOf
|
gptkb:chemical_compound
antineoplastic agent
vinca alkaloid
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01CA04
|
|
gptkbp:bioavailability_(oral)
|
40%
|
|
gptkbp:CASNumber
|
71486-22-1
|
|
gptkbp:category
|
antineoplastic agent
antimitotic agent
cytotoxic drug
|
|
gptkbp:chemicalFormula
|
C45H54N4O8
|
|
gptkbp:derivedFrom
|
catharanthine
vindoline
|
|
gptkbp:developedBy
|
gptkb:Pierre_Fabre_Laboratories
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Potier
|
|
gptkbp:eliminationHalfLife
|
27.7-43.6 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:first_approved_in
|
gptkb:France
|
|
gptkbp:first_approved_year
|
1989
|
|
gptkbp:hasInChIKey
|
QPUZJIKZOUCZNB-IBOSZNHHSA-N
|
|
gptkbp:hasSMILES
|
COC1=C2C3=C(C=CC(=C3)OC)C4C2N(C1)C5C4C6C7=CC=CC=C7N(C6CC5)C8=CC=CC=C8C(=O)OC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vinorelbine
|
|
gptkbp:KEGGID
|
D08670
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits microtubule assembly
|
|
gptkbp:meltingPoint
|
206-208°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
778.94 g/mol
|
|
gptkbp:origin
|
semi-synthetic
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
13.5%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
DB00361
5311497
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
constipation
neutropenia
|
|
gptkbp:synonym
|
gptkb:Navelbine
Eldisine derivative
|
|
gptkbp:UNII
|
6E3Z5PCO1S
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4_gene
|
|
gptkbp:bfsLayer
|
6
|